Per @pamelajeannoble, the letter flags contamination risks, manufacturing conditions and compounded copies resembling approved drugs.
Recap by typeshit. Post by @pamelajeannoble on Instagram.
Gounder notes the policy requires no testing of finished vials or deadline for side effect reports, and public comments on the draft run through November 13.
Healio
Durrani tells Healio the move bypassed rulemaking and FDA scientists, and warns patients may wrongly read it as FDA approval while long-term data is missing.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
A brief post argues buyers need accurate information on peptides because a lot of the popular messaging is misleading.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
Loading…